Cipla Limited

rs,

rip Code: CIPLA EQ 30th October, 2025 (1) BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Scrip Code: 500087 (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societ

INR 7,500

tant to only rely on the advice of a healthcare professional. 2 Highest-Ever Quarterly Revenue at INR 7,500+ Cr with Robust Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr

INR 7,589

st-Ever Quarterly Revenue at INR 7,500+ Cr with Robust Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue

8%

rly Revenue at INR 7,500+ Cr with Robust Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Busin

INR 1,895

at INR 7,500+ Cr with Robust Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Sna

0.5%

Cr with Robust Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Snapshot O

INR 1,351

st Profitability Revenue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Snapshot One India North Ame

4%

nue EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Snapshot One India North America One Afri

25%

EBITDA PAT Q2FY26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Snapshot One India North America One Africa E

18%

Y26 INR 7,589 Cr 8% (YoY) INR 1,895 Cr 0.5% (YoY) INR 1,351 Cr (YoY) 4% 25% of Revenue 18% of Revenue Business Performance Snapshot One India North America One Africa Emerging Markets &

INR 3,146

e Business Performance Snapshot One India North America One Africa Emerging Markets & Europe INR 3,146 Cr 7% (YoY) $ 233 Mn $ 134 Mn 5% (YoY) $ 110 Mn 15% (YoY) Q2FY26 Foracort ranked #1 brand i

7%

rformance Snapshot One India North America One Africa Emerging Markets & Europe INR 3,146 Cr 7% (YoY) $ 233 Mn $ 134 Mn 5% (YoY) $ 110 Mn 15% (YoY) Q2FY26 Foracort ranked #1 brand in the

“Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) Q2 FY26 - Global Consumer Wellness Franchise One India 2 1 Consumer brands in One India Revenue: INR 404 Cr One Africa Pain Relief Nicotine Replacement 2 2 Hydration Cold & Cough 2 Skin Infection Respi OTC Pain Management Consumer brands in South Africa Revenue: ZAR 437 Mn Cold & Cough Respi OTC Respi OTC 1.”

“market • Our manufacturing facility in Bommasandra, Bengaluru, has been classified as VAI by the USFDA during the quarter Pipeline Update • By Calendar year 2026, we expect to launch 4 major Respiratory assets, including gAdvair in Q4FY26, and 3 peptide assets, including Liraglutide.”

“Two AMR certified product - Azithromycin Dihydrate and Ciprofloxacin Achievement and Recognition Cipla’s case study on Energy Transition is selected in SB COP and will be featured in a special digital booklet in Nov 2025.”

Indicated as an adjunct to diet and exercise for

1

Registered Office

1

Indicated as an adjunct to diet and exercise for

• Type 2 Diabetes Treatment • Chronic Weight Management in adults with: ➢ Obesity (BMI ≥ 30) ➢ Overweight (BMI ≥ 27) + ≥1 weight- related comorbidity Market Impact & Accessibility • Expanded Reach: Partnership extends Tirzepatide availability beyond cities with Eli Lilly’s existing presence • Addressing Growing Health Concerns: ➢ ~101 Mn Indians with diabetes ➢ ~100 Mn Indians affected by obesity • Yurpeak introduces a new treatment option for these widespread conditions Product Availability & Dosage • Yurpeak- Available in KwikPen® Presentation • Pen Type: Multi-dose, single-patient-use prefilled pen • Doses per Pen: 4 fixed doses • Dosing Frequency: Once weekly • Available Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg 7 Empowering the Fight Against AMR: Cipla’s Stewardship CLICK TO EDIT MASTER TITLE STYLE Huena (Methenamine Hippurate) Zemdri (Plazomicin) Cipenmet (Novel anti-infective) ❑ Cipla introduces HUENA® – India’s first non-antibiotic drug for recurring urinary tract

Registered Office

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 17